Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz

RegulatoryapprovedWegovySanfilippo syndrome gene therapyPositive

AI Analysis

Summary

Ultragenyx received FDA approval for its Sanfilippo syndrome gene therapy while Novo Nordisk announced plans to reach $23B revenue by 2035 with continued workforce reductions and manufacturing capacity increases for Wegovy. Viking Therapeutics and Roche reported positive results for weight loss assets, amid ongoing IPO activity in the sector.

Financial Highlights

Revenue

$23B by 2035

Guidance

Novo Nordisk targets $23B in revenue by 2035

Outcome Details

FDA approval for Ultragenyx's Sanfilippo syndrome gene therapy

Importance:7/10

Sentiment:

0.30

weight lossgene therapyFDA approvalworkforce reductionmanufacturing expansionIPO

Related Companies

$NVO $VKTX $RHHBY $RARE

Read the original article

Published by BioSpace on September 23, 2026 10:11 AM

Read Original